Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Offering €6.20B in Senior Notes

NEW YORK – Danaher announced Tuesday that its European subsidiary priced an offering of €6.2 billion ($6.83 billion) in senior notes due between 2026 and 2049.

The company will offer €1.25 billion of .2 percent senior notes due in 2026; €1.25 billion of .45 percent senior notes due in 2028; €1.75 billion of .75 percent senior notes due in 2031; €1.25 billion of 1.35 percent senior notes due in 2039; and €750 million of 1.8 percent senior notes due in 2049.

The Washington, DC-based conglomerate said in a statement it plans to use the money to fund part of the cash consideration and other costs associated with its planned $21.4 billion acquisition of GE Life Sciences' Biopharma business. Danaher also said it may invest the proceeds in short-term bank deposits or investment-grade securities.

The company expects the offering to close on Sept. 18, 2019.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.